ストックスクリーナーアプリを入手
1.69
1.20%
0.02
アフターアワーズ：
1.72
0.03
+1.78%
Prokidney Corp (PROK) 最新ニュース
ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock - Stock Titan
[Form 3] PROKIDNEY CORP. Initial Statement of Beneficial Ownership - Stock Titan
Identiv And Two Other Penny Stocks To Watch Closely - simplywall.st
PROK: Phase III cell therapy for advanced CKD targets dialysis delay, with pivotal data due in 2027 - TradingView
ProKidney appoints Kenneth Locke as chief technical officer - The Pharma Letter
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout - The Business Journals
ProKidney expands executive management team with chief technical officer - Winston-Salem Journal
Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer - marketscreener.com
ProKidney names Kenneth Locke as chief technical officer By Investing.com - Investing.com Australia
ProKidney Corp. Appoints Kenneth Locke as Chief Technical Officer - geneonline.com
ProKidney names Kenneth Locke as chief technical officer - Investing.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer - The Manila Times
ProKidney shareholders reaffirm board and auditor at 2026 meeting - The Globe and Mail
PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant - Stock Titan
Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation - Stock Titan
ProKidney (PROK) director receives 135,000 stock options grant as compensation - Stock Titan
ProKidney (PROK) director awarded 135K stock options as compensation - Stock Titan
ProKidney (NASDAQ: PROK) grants 135,000 stock options to director - Stock Titan
[Form 4] PROKIDNEY CORP. Insider Trading Activity - Stock Titan
PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award - Stock Titan
ProKidney (NASDAQ: PROK) 2026 meeting backs board nominees and EY - Stock Titan
ProKidney Corp. (PROK) Edges Higher Amid Continued Support: Potential for Breakout Above $1.94 ResistanceHigh Conviction Picks - The Legal Advocate
PROK: Director elections and auditor ratification passed; rilparencel Phase III on track for 2026 - TradingView
ProKidney Corp. (PROK) Jumps Over 7% as Biotech Stock Tests Resistance at $1.90Synthetic Long - The Legal Advocate
Number of shareholders of ProKidney Corp. – NASDAQ:PROK - TradingView
PROK Technical Analysis | Trend, Signals & Chart Patterns | PROKIDNEY CORP (NASDAQ:PROK) - ChartMill
PROK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market - TipRanks
ProKidney's first-quarter loss grows with increased operating expenses - Winston-Salem Journal
BofA Securities Maintains ProKidney(PROK.US) With Sell Rating, Announces Target Price $1 - Moomoo
ProKidney Corp. (PROK) reports Q1 loss, tops revenue estimates - MSN
ProKidney Releases Q1 2026 Financial Results - AlphaStreet
Prokidney Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ProKidney reports Q1 EPS (14c), consensus (14c) - TipRanks
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial - TipRanks
ProKidney Q1 loss widens as R&D spending rises - TradingView
PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary - TradingView
PROK: Phase 3 trial enrollment on track; cash runway extends into mid-2027 amid rising R&D costs - TradingView
ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results - Quiver Quantitative
PROK: Net loss widened to $42.6M in Q1 2026 as R&D spending rose for Phase 3 trials - TradingView
[8-K] PROKIDNEY CORP. Reports Material Event - Stock Titan
ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027 - Stock Titan
Kidney disease cell therapy ProKidney eyes key 2027 trial results - Stock Titan
BRIEF-ProKidney Q1 Operating Income USD -44.933 Million - TradingView
Press Release: ProKidney Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
TradingKey - TradingKey
PROKIDNEY CP (PROK) Eps Diluted (TTM) - Zacks Investment Research
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $600M - Sahm
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
ProKidney approaches pivotal research, funding crossroads for drug therapy - Winston-Salem Journal
ProKidney Names Greg Madison as Chief Commercial Officer - HarianBasis.co
PROK - Finviz
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):